Osimertinib
astrazeneca
['osimertinib']
cofellow simulates clinical and financial implications of the adura trial on a real world patient population. she posits that osimertinib would cost 450k more than soc, improved 5y dfs by 35.4%, and prevented recurrence in 58%. #asco23 
He/him. Heme/Onc Fellow @ClevelandClinic | Chief Res @Metrohealth | learning how to be a better human | all of my chirpings and re-chirpings = my own|